FBRX beat EPS expectations by 5.19%
May 23, 2024, 3:34 AM
-12.72%
What does FBRX do
Forte Biosciences, Inc., a Dallas-based biopharmaceutical company, focuses on developing dermatology products like FB-102, targeting autoimmune diseases such as GvHD, vitiligo, and alopecia areata. Incorporated in 2017, the company has subsidiaries including Forte Subsidiary, Inc. and Forte Biosciences Emerald Limited, and employs 9 people.
Forte Biosciences Inc (FBRX) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Forte Biosciences Inc's actual EPS was -$0.16, beating the estimate of -$0.17 per share, resulting in a 5.19% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.